Abraham Abbey Paul

Dr. Abraham Abbey Paul

Biotechnology Engineering, Ben-Gurion University of the Negev, Beersheba, Southern, Israel
orcid
Postdoctoral Associate

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2022 in Materials Today Communications
Verified
Journal Article
Closed access
JBJugal Barman
Jugal Barman
ATAkriti Tirkey
Akriti Tirkey
SBShivani Batra
Shivani Batra
Abraham Abbey PaulAbraham Abbey Paul
Abraham Abbey Paul
KPKingshuk Panda
Kingshuk Panda
PBPunuri Jayasekhar Babu
Punuri Jayasekhar Babu

Verified
Journal Article
Open access
PDF file
Victor MarkusVictor Markus
Victor Markus
Abraham Abbey PaulAbraham Abbey Paul
Abraham Abbey Paul
Kerem TeralıKerem Teralı
Kerem Teralı
NÖNazmi Özer
Nazmi Özer
Robert MarksRobert Marks
Robert Marks
AKAriel Kushmaro
Ariel Kushmaro
An imbalance in gut microbiota, termed dysbiosis, has been shown to affect host health. Several factors, including dietary changes, have been reported to cause dysbiosis with its associated pathologies that include inflammatory bowel disease, cancer, obesity, depression, and autism. We recently demonstrated the inhibitory effects of artificial sweeteners on bacterial quorum sensing (QS) and proposed that QS inhibition may be one mechanism behind such dysbiosis. QS is a complex network of cell–cell communication that is mediated by small diffusible molecules known as autoinducers (AIs). Using AIs, bacteria interact with one another and coordinate their gene expression based on their population density for the benefit of the whole community or one group over another. Bacteria that cannot synthesize their own AIs secretly “listen” to the signals produced by other bacteria, a phenomenon known as “eavesdropping”. AIs impact gut microbiota equilibrium by mediating intra- and interspecies interactions as well as interkingdom communication. In this review, we discuss the role of QS in normobiosis (the normal balance of bacteria in the gut) and how interference in QS causes gut microbial imbalance. First, we present a review of QS discovery and then highlight the various QS signaling molecules used by bacteria in the gut. We also explore strategies that promote gut bacterial activity via QS activation and provide prospects for the future.

23 January 2024 in Biosensors
Verified
Journal Article
Open access
PDF file
Abraham Abbey PaulAbraham Abbey Paul
Abraham Abbey Paul
AAAdedamola Aladese
Adedamola Aladese
Robert MarksRobert Marks
Robert Marks
Three-dimensional (3D) printing technology, also known as additive manufacturing (AM), has emerged as an attractive state-of-the-art tool for precisely fabricating functional materials with complex geometries, championing several advancements in tissue engineering, regenerative medicine, and therapeutics. However, this technology has an untapped potential for biotechnological applications, such as sensor and biosensor development. By exploring these avenues, the scope of 3D printing technology can be expanded and pave the way for groundbreaking innovations in the biotechnology field. Indeed, new printing materials and printers would offer new possibilities for seamlessly incorporating biological functionalities within the growing 3D scaffolds. Herein, we review the additive manufacturing applications in biosensor technologies with a particular emphasis on extrusion-based 3D printing modalities. We highlight the application of natural, synthetic, and composite biomaterials as 3D-printed soft hydrogels. Emphasis is placed on the approach by which the sensing molecules are introduced during the fabrication process. Finally, future perspectives are provided.

1 September 2024 in Engineered Regeneration
Verified
Journal Article
Open access
PBPunuri Jayasekhar Babu
Punuri Jayasekhar Babu
ATAkriti Tirkey
Akriti Tirkey
Abraham Abbey PaulAbraham Abbey Paul
Abraham Abbey Paul
KKKathelina Kristollari
Kathelina Kristollari
JBJugal Barman
Jugal Barman
RMRobert S. Marks
Robert S. Marks

5 March 2025 in Analytical Letters
Verified
Journal Article
Closed access
VMVictor Markus
Victor Markus
Abraham Abbey PaulAbraham Abbey Paul
Abraham Abbey Paul
RMRobert S. Marks
Robert S. Marks
JCJude Caleb
Jude Caleb

1 November 2024 in Chemosensors
Verified
Journal Article
Open access
PDF file
KKKathelina Kristollari
Kathelina Kristollari
Abraham Abbey PaulAbraham Abbey Paul
Abraham Abbey Paul
SASagi Angel
Sagi Angel
Robert MarksRobert Marks
Robert Marks
Differentiated thyroid carcinoma (DTC) is among the most prevalent endocrine cancers. The diagnosis of DTC has witnessed tremendous progress in terms of technological advancement and clinical operational guidelines. DTC diagnostics have evolved significantly over centuries, from early clinical examinations to modern molecular testing and imaging modalities. The diagnosis and management of DTC are currently dependent on the international histological classification and identification of specific genetic abnormalities in tumor tissue, as well as the prognostic implications that can inform treatment decisions. This study goes down the memory lanes of various diagnostic methods for DTCs, highlighting recent advancements in molecular testing and point-of-care (POC) technology. Beginning with conventional methods like fine needle aspiration biopsy (FNAB), fine needle aspiration cytology (FNAC), and ultrasound (US) and moving to contemporary innovative approaches such as POC-thyroglobulin (POC-Tg) and liquid biopsy, this review showcases the current trends in DTC diagnostics. Although considerable progress has been achieved in early malignancy detection, patient stratification, prognosis, and personalized treatment, there is a need to refine the mainstay diagnostic procedures. Finally, future perspectives were provided, and emerging roles of artificial intelligence in DTC diagnostics were explored.